Optimization of the postembolization period in patients with uterine myoma

Objective. To investigate the efficacy of a venous protector in the complex relief of postembolization syndrome in patients with uterine myoma after uterine artery embolization (UAE). Subjects and methods. 30 patients with uterine myoma and signs of venous/lymphatic insufficiency in the legs (Group 1) were given a venous protector (hesperidin 50 mg, diosmin 450 mg) as one tablet (500 mg) twice daily for one month on the first day following UAE. A control group (Group 2) consisted of 30 patients with post- UAE uterine myoma and without signs of venous/lymphatic insufficiency in the legs, who were not treated with a venous protector. The patients of the analyzed groups were matched for age, the location, size, and number of myomatous nodes. The time course of changes in the regression of myomatous nodes was assessed from ultrasonographic findings at 3 months after UAE. The degree of post- UAE pain syndrome was estimated using a 10-point scale. Results. All the patients described the nature of pain syndrome in the first week after UAE equally; however, the 10-point scale intensity was much more pronounced in Group 2. Regression of myomatous nodes was more pronounced in Group 1 patients (36.5% versus 20.3%). Conclusion. The findings may suggest that venous protective therapy can be used in patients undergoing UAE as a technique to optimize X-ray endovascular treatment and to reduce the severity of postembolization syndrome especially in patients with uterine myoma and venous/lymphatic insufficiency in the lower limbs.

uterine artery embolization, uterine myoma, postembolization syndrome, venous/lymphatic insufficiency, venous protectors